XSAT:HAMLET B (Sweden)
Â
Ordinary Shares - Class B
kr
6.67
-0.13 (-1.91%)
Aug 17
Business Description
Hamlet BioPharma AB publ
ISIN : SE0015661152
Share Class Description:
XSAT:HAMLET B: Ordinary Shares - Class BTotal Employee Number:
7Compare
Compare
Traded in other countries / regions
HAMLET B.Sweden7ZT.Germany IPO Date
2015-10-23Description
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -19 | |||||
3-Year EPS without NRI Growth Rate | 41 | |||||
3-Year FCF Growth Rate | -7.4 | |||||
3-Year Book Growth Rate | -14.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.82 | |||||
9-Day RSI | 30.52 | |||||
14-Day RSI | 35.71 | |||||
3-1 Month Momentum % | 3.02 | |||||
6-1 Month Momentum % | 45.91 | |||||
12-1 Month Momentum % | 40.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.12 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 2.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.6 | |||||
Shareholder Yield % | -3.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -130.95 | |||||
ROA % | -115.07 | |||||
ROIC % | -181.95 | |||||
3-Year ROIIC % | -114.9 | |||||
ROC (Joel Greenblatt) % | -17072.95 | |||||
ROCE % | -131.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 34.56 | |||||
Price-to-Tangible-Book | 95.29 | |||||
EV-to-EBIT | -21.82 | |||||
EV-to-EBITDA | -26.52 | |||||
EV-to-FCF | -28.17 | |||||
| Price-to-Net-Current-Asset-Value | 95.29 | |||||
| Price-to-Net-Cash | 133.4 | |||||
Earnings Yield (Greenblatt) % | -4.58 | |||||
FCF Yield % | -3.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hamlet BioPharma AB publ Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.315 | ||
| Beta | 0.717 | ||
| 3-Year Sharpe Ratio | 0.68 | ||
| 3-Year Sortino Ratio | 1.7 | ||
| Volatility % | 52.03 | ||
| 14-Day RSI | 35.71 | ||
| 14-Day ATR (kr) | 0.347568 | ||
| 20-Day SMA (kr) | 7.1115 | ||
| 12-1 Month Momentum % | 40.19 | ||
| 52-Week Range (kr) | 4 - 8.96 | ||
| Shares Outstanding (Mil) | 190.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hamlet BioPharma AB publ Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hamlet BioPharma AB publ Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-12 | In 178 days | ||
| General meeting for 2026 | 2026-11-20 | In 94 days | ||
| First quarter earnings results for 2027 | 2026-11-13 | In 87 days | ||
| Annual report for 2026 | 2026-10-30 | In 73 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 10 days | ||
| Third quarter earnings results for 2026 | 2026-05-22 | 7.79 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-13 | 5.04 (+1.72%) | ||
| General meeting for 2025 | 2025-12-04 11:00 | 4.92 (+0.31%) | ||
| First quarter earnings results for 2026 | 2025-11-14 | 4.82 (+2.67%) | ||
| Annual report for 2025 | 2025-10-31 | 4.87 (-2.70%) |
Show
Entries
Hamlet BioPharma AB publ Frequently Asked Questions
What is Hamlet BioPharma AB publ(XSAT:HAMLET B)'s stock price today?
The current price of XSAT:HAMLET B is kr6.67. The 52 week high of XSAT:HAMLET B is kr8.96 and 52 week low is kr4.00.
When is next earnings date of Hamlet BioPharma AB publ(XSAT:HAMLET B)?
The next earnings date of Hamlet BioPharma AB publ(XSAT:HAMLET B) is 2026-08-28.
Does Hamlet BioPharma AB publ(XSAT:HAMLET B) pay dividends? If so, how much?
Hamlet BioPharma AB publ(XSAT:HAMLET B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Hamlet BioPharma AB publ
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers